HOUSTON, TX–(Marketwire – September 28, 2010) –  Four nationally recognized orthopedic surgeons from the Methodist Center for Orthopaedic Surgery are now seeing patients in northwest Houston at Methodist Willowbrook Hospital. 

The Willowbrook center, which provides comprehensive care in the diagnosis and surgical and non-surgical treatment of musculoskeletal injuries and conditions, is made up of board certified specialists in hand and upper extremity, foot and ankle, sports injuries and orthopedic trauma.

Drs. Korsh Jafarnia, Travis Hanson, Bruce Moseley, and Plinio Caldera have joined the center, now providing complete orthopedic and sports medicine care to northwest Houston and the surrounding area. 

“We are pleased to add these talented physicians to our team and the dynamic orthopedic center at Methodist Willowbrook. Utilizing the latest technology in arthroscopy, endoscopy and rehabilitative therapies, these physicians — each specializing in a particular area — bring a superior level of care to the community,” said Julie Peterson, Director, Physician and Community Strategic Alignment, Methodist Willowbrook Hospital.

Jafarnia, who is also Chief of Staff at Methodist Willowbrook Hospital, is one of Houston’s leading hand and upper extremity surgeons. He is an assistant clinical professor at Baylor College of Medicine and completed his fellowship at Massachusetts General Hospital at Harvard Medical School. Hanson specializes in sports medicine with particular focus on the foot and ankle. He is a team physician for Rice University and the U.S. Soccer national teams. Moseley specializes in sports medicine with focus on the knee and shoulder. He is the recipient of the DeBakey Award for Outstanding Research and formerly team physician for the Houston Rockets and the Houston Comets. Caldera specializes in orthopedic trauma with focus on the knee, shoulder and hip. He has a special interest in arthroscopic knee, shoulder surgery and total hip and knee replacements.

To learn more about these physicians and the Methodist Center for Orthopaedic Surgery at Willowbrook go to www.methodistwillowbrook.com or call (281) 737-0999.

Click here to see all recent news from this company

MINNEAPOLIS, MN–(Marketwire – September 28, 2010) – Sunlight Research™ — The Source for Patent Analysis www.SunlightResearch.com, today announced the October 6, 2010 release of its Induced Pluripotent Stem Cell Patent Report analyzing this important stem cell technology segment. 

Stem cells have the remarkable potential to replace and rejuvenate injured, diseased and aging tissues. With the development of induced pluripotent stem cell (iPSC) technologies, differentiated cells with the exact genetic and immunological properties of a selected patient’s cells can be reprogrammed to be stem cells, thereby eliminating problems of immunological rejection and viral contamination.

“Induced pluripotent stem cells may be developed for treatment of a multitude of diseases, including cardiovascular and neurological conditions” says Robin A. Chadwick, PhD, JD, a patent attorney and lead author of Sunlight’s iPSC Patent Report. “In addition, iPSCs can end long waiting periods for organ transplants, and the use of immunosuppression drugs in transplant recipients. The process,” she explains, “could be as simple as mixing a few cells from a patient with a [patented] cocktail of biological molecules, letting the cells grow up, and then injecting them into the patient.”

Daniel A. Halpern, President of Sunlight Research, noted that “iPSCs represent a real game-changing technology, and one of the most exciting segments of the rapidly growing stem cell market.” The overall global stem cell market is projected to reach $2.6 billion by 2012, and to exceed $5.1 billion by 2014, according to estimates by Business Insights, a market research firm. Other estimates show considerably larger global market forecasts. “The gold rush is on,” Mr. Halpern added, “and many businesses and research institutions are staking claims to various aspects of iPSC technology, as evidenced by patent filings and issuances. Our mission is to shed light on these boundary-setting activities so that all stakeholders can make better decisions.” 

Webinar October 6, 2010
The webinar, which will be webcast live from the World Stem Cell Summit in Detroit, is scheduled for 12:00pm EDT on Wednesday, October 6, 2010 and will highlight key findings of Sunlight’s comprehensive claims-level analysis of the iPSC patent landscape, including issued patents and pending patent applications. Registration and report details are available online at iPSC Patent Report.

About Sunlight Research, LLC
Sunlight Research™ is the premier source for up-to-date Reports, Webinars and Educational Events concerning Patent Claims Coverage, Intellectual Property Market Research, Non-Practicing Entity (“Troll”) Patent Reports and Interactive Freedom-To-Operate databases. Sunlight provides timely, in-depth and actionable patent analyses that are easily accessible and cost effective. A key feature of many Sunlight reports is an interactive freedom-to-operate tool, which allows customers to rapidly test various product designs for infringement against relevant patents. Sample reports are available at www.SunlightResearch.com

Register Today
iPSC Patent Report.

About the World Stem Cell Summit
The summit will attract more than 1,000 attendees from 30 nations, 60 exhibitors and more than 200 endorsing organizations and media partners. The largest and most comprehensive multi-track stem cell conference, the Summit features more than 150 international speakers and 50 hours of in-depth science, business and society presentations. www.worldstemcellsummit.com.

Keywords: Induced Pluripotent Stem Cells, iPSCs, stem cell patent, biotech, biotechnology, world stem cell summit, claims, transplants

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – September 28, 2010) – Hospital acquired infections, or HAIs remain a problem for the healthcare system, and a problem in which new diagnostic products can play a role, according to Kalorama Information. In its report, “The Worldwide Market for In Vitro Diagnostic Tests,” the healthcare market research publisher details how sophisticated molecular tests that can quickly identify patients for isolation and treatment are being utilized despite their higher price tag. Kalorama forecasts that revenues for molecular tests that detect HAIs will grow at 25% per year for the next five years.

“They are growing at four times the rate of the average IVD products,” said Shara Rosen, senior diagnostic analyst for Kalorama Information and the author of the report. “HAIs are a huge problem and this is an opportunity for the most logical tests to treat them.”

Centers for Disease Control and Prevention (CDC) estimates that HAIs affect nearly 2 million Americans annually, resulting in 90,000 deaths and up to $6.5 billion in extra costs. A 2009 edition study in the Journal of the American Medical Association found that 51% of patients in nearly 1,300 intensive care units in 75 countries were suffering from some kind of hospital-acquired infection. MRSA, the most notorious of them all, accounts for about 10% of these infections. Other problem pathogens include C-difficile (an intestinal infection), Vancomycin-Resistant Enterococcus (linked with intestinal, skin and blood infections), and drug-resistant Acinetobacter (which can cause pneumonia, skin and blood infections). 

Kalorama Information’s report details several approaches to HAI detection. On the conservative and least expensive side are chromogenic growth media that permit the selective growth of MRSA bacteria and produce a colored colony that is easily recognizable. On the more expensive side, there has been an explosion of user-friendly molecular assays that have been widely accepted. Cephid, Becton Dickinson and Seegene are among the companies with products to test for HAIs. The advantage of these molecular tests is that they can provide highly sensitive rapid turnaround results. Their popularity, according to the report is growing but not universal.

“Screening with molecular tests has its defenders and opponents,” Rosen said. “The defenders suggest that the cost of molecular screening tests, especially for MRSA, allow carrier patients to be segregated from the rest of the population. The opponents say that techniques such as chromogenic growth media identify carriers in enough time to limit the damage they can do.”

Kalorama Information’s Report, “The Worldwide Market for In Vitro Diagnostic Tests,” takes a look at these topics and more. The book, published every two years, looks at every aspect of the in vitro diagnostic industry including molecular, hematology, immunoassays, POC and more. The report can be found at:
http://www.kaloramainformation.com/redirect.asp?progid=79688&productid=2613362.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

HOUSTON, TX–(Marketwire – September 28, 2010) –  Bay Area Gastroenterology, a Houston Gastroenterology practice, is now pleased to offer Remicade infusions for patients with Crohn’s and Ulcerative colitis, at 1015 Medical Center Boulevard in Webster, Texas. With their state of the art infusion suites, the physicians at Bay Area Gastroenterology continue to be one the leading endoscopy practices in Houston and Clear Lake. 

The infusion suites offer IV infusion of Remicade on weekdays by trained nurses in an office setting. The gastroenterology consultants are Board certified trained professionals who have expertise in the diagnosis and therapy of Inflammatory bowel disorders such as Crohn’s disease, Ulcerative colitis and Colitis. Dr. Ravi S. Mani M.D., President of Bay Area Gastroenterology, states that the disease is often characterized by abdominal pain, diarrhea, bleeding, change in bowel habits and weight loss.

Patients who have moderate to severe Crohn’s Disease and who have not responded to other therapies are good candidates for Remicade infusions. Remicade has been effective in relieving the symptoms of acute abdominal pain and inflammatory bowel disorders by binding and blocking the effects of TNF-alpha, a protein involved in the inflammation process. 

Remicade IV Infusions at Bay Area Gastroenterology are administered by highly trained nurses in the comfort of an infusion suite. During the infusion, the nurse will check each patient at regular intervals. Patients are encouraged to relax, read a book, listen to music or watch television.

“We are pleased to offer IV Infusion for Crohn’s Disease and Ulcerative colitis at Bay Area Gastroenterology,” said Dr. Mani. “It is far more relaxing for our patients to receive this therapy in one of our Infusion suites instead of having to go to the hospital. Our nurses are highly trained in the administration of IV infusions and ensure the comfort of each patient throughout the infusion process.”

About Bay Area Gastroenterology
Bay Area Gastroenterology is a leading medical center for the diagnosis and treatment of ailments of the stomach, intestines, colon, gallbladder and pancreas. On site radiological and endoscopic facilities provide state-of-the-art medical care for disorders and diseases such as Crohn’s, Colitis and acid reflux/GERD. Bay Area Gastroenterology was the first private practice group in the Houston area to offer office based Virtual Colonoscopy for screening of colon cancer.

Click here to see all recent news from this company

WEST HARTFORD, CT–(Marketwire – September 28, 2010) –  BroadcastMed, the leader in online medical video, presents on ORLive a live interactive broadcast of a patient specific knee replacement featuring technology from Zimmer. This week also includes the launch of a new CME focused website from UPMC, the UPMC Physician Resources site.

On-demand features this month include our library of procedures and educational programming focused on atrial fibrillation and BroadcastMed invites you to take part in the latest installment of the Virtual Brain Tumor Board.

NEW ON ORLIVE

LIVE SURGERY VIDEO – Zimmer Patient Specific Instruments and the Gender Solutions™ Natural-Knee® Flex System
Premieres Tuesday, September 28, 2010 at 7PM EDT

On Tuesday, September 28th at 7 PM EDT Zimmer Medical Education will broadcast an ORLive Zimmer Patient Specific Instrument surgery featuring Zimmer Patient Specific Instruments and Natural Knee. The surgery will be performed by Dr. Michael Bolognesi, Duke University Medical Center and will be moderated by Dr. Shawn Hocker from Atlantic Orthopedics, PA in Wilmington, NC. The broadcast will last one hour and will show the entire surgical procedure.

This surgery video is available exclusively to members of the ORLive community, and members can interact and ask questions via the ORLive website. Learn more about this broadcast or get a reminder at ORLive.com, and be ready to view this exciting procedure by activating your free membership to ORLive today.

NEW CME SITE – Introducing the UPMC Physician Resource
This week marks the launch of the UPMC Physician Resources website, a new web destination dedicated to providing physicians with the highest quality CME content from one of the country’s leading institutions.

ORLIVE REFERRALS – Week of September 27, 2010
September is National Atrial Fibrillation Awareness Month, and each week ORLive highlights on-demand videos for our membership and visitors. 

Medical Education Referral: Arrhythmia: Catheter Ablation for Supraventricular Tachycardia (SVT), from Brigham and Women’s Hospital

CME Referral: Reality EP: Catheter Ablation for Paroxysmal AF, from the Heart Rhythm Society

Viewer’s Referral: Robot Assisted Partial Nephrectomy Surgery, from Shawnee Mission Medical Center

HIGHLIGHTS

NOW ON-DEMAND – Continuum® Acetabular System and Zimmer® M/L Taper with Kinectiv® Technology
Now Available On-demand

Zimmer Medical Education presents an ORLive Total Hip Arthroplasty featuring the Continuum Acetabular System and the Kinectiv Modular Neck Technology. The surgery will be performed by Dr. Mark Hartzband, Hartzband Center for Hip and Knee Replacement, L.L.C., Paramus, NJ and will be moderated by Dr. Paul Duwelius, St. Vincent Hospital, Portland, OR. The broadcast will last one hour and will show the entire surgical procedure. Following the live broadcast the surgery will be archived for future playback.

This opportunity allows for firsthand insight of the safe and effective implantation and surgical procedure involved with the Continuum® Acetabular System and the Zimmer® M/L Taper with Kinectiv® Technology.

This surgery video is available exclusively to members of the ORLive community, and members can interact and ask questions via the ORLive website. Learn more about this broadcast or get a reminder at ORLive.com, and be ready to view this exciting procedure by activating your free membership to ORLive today.

NOW ON-DEMAND – Artificial Disc Treatments for Cervical Disease
Now Available On-Demand

Until recently, spinal fusion was the surgical solution to cervical disc disease. ORLive invites you to watch footage of an Artificial Discectomy performed by William Kuhn, MD of Halifax Hospital, and join in on a live online discussion with the doctor and patient, Ali Rabatsky. 

Viewers of this video are invited to interact with the team via the ORLive website, where you can also request a reminder to alert you when this video is going live.

PREVIEW – LEGION™ Total Knee System with VISIONAIRE™ Patient Matched Instrumentation
Premieres Tuesday, October 5, 2010 at 7PM EDT

Kenneth Cherry, MD will demonstrate his approach to address efficiency in the OR by utilizing the LEGION Total Knee System in conjunction with VISIONAIRE Patient Matched Instrumentation while Dr. Steven Haas, from the Hospital for Special Surgery in New York City, moderates the procedure. Combining the two technologies, will reduce OR time and eliminate up to 23 surgical steps from the TKA procedure thereby making efficiency more accessible.

Learn more about this broadcast or get a reminder at ORLive.com, and be ready to view this exciting procedure by activating your free membership to ORLive today.

About BroadcastMed

BroadcastMed is the leading provider of video communication channels and solutions to the healthcare community. Working collaboratively with hospitals, device manufacturers, and pharmaceutical companies, BroadcastMed produces and distributes customized, interactive, video programs that demonstrate the latest advances in medicine, surgical techniques and product innovations, and promotes them to a verified audience of more than 700,000 healthcare professionals. The BroadcastMed network of sites provides an intimate look at over 650 live and on-demand surgeries, medical education, and symposia to global audiences that watch and learn from more than 40 million video views annually. The BroadcastMed network can be found on-line at www.BroadcastMed.com. 

id=”nav_links”>

WEST HARTFORD, CT–(Marketwire – September 27, 2010) –  ORLive, a leading provider of online video to the healthcare market, announces the formation of BroadcastMed, to address the growing demand for online video solutions. 

BroadcastMed is a response to the changes in the market that extend far beyond the traditional ORLive solutions of live programming from the Operating Room. “Our company long ago accomplished the mission implied by the name ORLive. We literally have taken physicians and other healthcare professionals ‘Live to the OR,'” says Ross Joel, CEO of BroadcastMed. “As a rapidly increasing number of healthcare professionals turn to online resources for education and research, we have a growing audience and clients who have interests that stretch well beyond surgery to all medical disciplines. BroadcastMed meets those diverse needs with strategic consulting, program development, and audience generation solutions.”

BroadcastMed communicates, demonstrates and educates through websites such as ORLive.com and The Virtual Brain Tumor Board. Where ORLive.com will continue to bring the most relevant surgically-focused content to an ever growing online audience, look for a soon to be launched site for CME focused video on BroadcastMedCME.com, a site dedicated to providing access to online accredited continuing medical education.

The formation of BroadcastMed marks a new milestone for the 16 year old company, enabling new growth opportunities. “While our increasing strength and diversity make BroadcastMed the cornerstone of our branding worldwide, given the significance of our flagship web brand, ORLive, its structure, focus and name will remain unchanged,” says Peter Gailey, President of BroadcastMed. Gailey also says, “This is a very exciting time in the market and we see this as a step towards providing doctors, nurses and other clinicians with high quality and relevant online content via a trusted source.”

About BroadcastMed
BroadcastMed is the leading provider of video communication channels and solutions to the healthcare community. Working collaboratively with hospitals, device manufacturers, and pharmaceutical companies, BroadcastMed produces and distributes customized, interactive, video programs that demonstrate the latest advances in medicine, surgical techniques and product innovations, and promotes them to a verified audience of more than 700,000 healthcare professionals. The BroadcastMed network of sites provides an intimate look at over 650 live and on-demand surgeries, medical education, and symposia to global audiences that watch and learn from more than 40 million video views annually. The BroadcastMed network can be found on-line at www.BroadcastMed.com.

id=”nav_links”>

SAN JOSE, CA–(Marketwire – September 27, 2010) –  Efforts to educate uninsured Americans who are unaware of current government-funded and low-cost health insurance programs have been given a boost with the Foundation for Health Coverage Education’s (FHCE) launch today of a Spanish language edition of its pioneering website, www.CoverageForAll.org. 

The nonprofit was able to translate CoverageForAll.org and expand its outreach to the Hispanic community with the support of a $30,000 grant from the Aetna Foundation, the independent philanthropic arm of Aetna Inc. The Spanish version, http://espanol.coverageforall.org will provide Spanish-speaking visitors with the same content found in FHCE’s main public and private health coverage state-by-state directory of programs, which has been educating uninsured Americans about their coverage options since 2004.

“At a time when health care reform legislation is requiring people to have health insurance coverage, we need to move with even greater urgency to break down barriers, such as language, to information about government-funded or low-cost programs,” said Anne C. Beal, M.D., M.P.H., president of the Aetna Foundation. “We are heartened that the new Spanish-language version of CoverageForAll.org will enable a significant segment of the American population to have affordable access to our health care system. Establishing a level playing field for all racial and ethnic groups to obtain good health care is a priority program area for the Aetna Foundation.” 

With this new enhancement, CoverageForAll.org visitors can simply click on http://espanol.coverageforall.org and learn their health insurance options in Spanish through FHCE’s 5-question Eligibility Quiz or they can call the 24/7 multilingual U.S. Uninsured Help Line (1-800-234-1317) to talk with a Spanish-speaking health insurance specialist who will review the questions with them. This eligibility review is a starting point for the Fresno, California-based call center’s counselors who guide each caller through their options and direct them to the appropriate state-sponsored programs. Along with taking the Eligibility Quiz, visitors now also have the ability to learn about COBRA coverage via the Spanish-version of FHCE’s COBRA Booklet or may download FHCE’s Health Care Options Matrix, the consumer-friendly guide to all of the health coverage programs in their state.

The goal of FHCE for translating the site was to broaden its mission of lowering the ranks of the uninsured, specifically by targeting what the U.S. Census Bureau indicates is the 32% of Hispanic Americans who live without health coverage. The Aetna Foundation’s grant opened up an even larger opportunity to assist the FHCE’s current collaborative partners, the American Cancer Society, the American Heart Association, the American Lung Association, the American Diabetes Association, and California’s Employee Development Department and Department of Insurance in aiding their Hispanic populations.

“The FHCE has helped more than two million people find heath coverage through CoverageForAll.org and our U.S. Uninsured Help Line,” said Ankeny Minoux, President of the FHCE. “With funding from the Aetna Foundation for a Spanish version of CoverageForAll.org, we can continue to provide uninsured Americans an easy and efficient way to access information about their health coverage options in their native language.”

About the Aetna Foundation
The Aetna Foundation is the independent charitable and philanthropic arm of Aetna Inc. Since 1980, Aetna and the Aetna Foundation have contributed over $379 million in grants and sponsorships, including more than $20 million in 2009. As a national health foundation, we promote wellness, health, and access to high-quality health care for everyone. This work is enhanced by the time and commitment of Aetna employees, who have volunteered nearly two million hours since 2003. Our current giving is focused on addressing the rising rate of adult and childhood obesity in the U.S.; promoting racial and ethnic equity in health and health care; and advancing integrated health care. For more information, visit www.AetnaFoundation.org.

About the Foundation for Health Coverage Education:

The Foundation for Health Coverage Education (FHCE) is a non-profit 501 (c) 3 organization with a mission to help simplify public and private health insurance eligibility information in order for more people to access coverage. In addition to its U.S. Uninsured Help Line (800) 234-1317 and website www.CoverageForAll.org, FHCE offers free consumer guides, such as the Health Care Options Matrix™ that is available for all 50 states.

Click here to see all recent news from this company

FARGO, ND–(Marketwire – September 27, 2010) –  Intelligent InSites Inc., the leading provider of real-time enterprise visibility and automation solutions, has announced recipients of its 2010 Excellent InSites Awards. The awards recognize organizations that are transforming healthcare through their use of the InSites Enterprise Visibility Platform™ (InSites Platform) to drive significant, measureable, and sustainable financial and quality of care improvements. Intelligent InSites honored clients and partners during its Second Annual Partner Summit, which was held in Fargo, ND on September 13-15, 2010.

Client Awards for 2010 were awarded in two categories:

Innovation Award, received by Butler Health System (www.butlerhealthsystem.org), recognizes the Intelligent InSites client who has leveraged the InSites Platform in groundbreaking ways, exhibiting creativeness in the application of technology to improve the level of care, patient/resident safety, operational efficiency, compliance and staff satisfaction, and creating the real-time enterprise.

Impact Award, received by Texas Health Resources (www.texashealth.org), recognizes an exceptional Intelligent InSites client using the InSites Platform to make a significant and quantifiable impact on patient/resident care, operational efficiency, and staff satisfaction.

“We are extremely proud to recognize Butler Health System and Texas Health Resources,” said Mark Rheault, President and CEO of Intelligent InSites. “Both organizations have demonstrated their commitment to finding new ways to improve their operations as well as ensure the best experience for their patients. It is very gratifying to know that our solution helps fulfill their vision and goals, and has done so with exceptional and sustainable outcomes.”

Partner Awards for 2010 were presented to the following organizations:

Alliance Partner of the Year Award – Crothall Services Group (www.crothall.com)
Integration Partner of the Year Award – Awarepoint (www.awarepoint.com)
OEM Partner of the Year Award – Touchtown (www.touchtown.us)
Reseller Partner of the Year Award – West-Com Nurse Call Systems (www.westcall.com) and Comm-Tronics (www.comm-tronics.net)

“The recipients of these annual partner awards have all demonstrated the actions in alignment with the mission of Intelligent InSites and therefore have profoundly improved the safety, satisfaction, and quality of life of our mutual clients and the people they serve,” said Jim Traynor, Director of Partnerships at Intelligent InSites.

The Intelligent InSites Partner Summit is focused on how software and technology providers, resellers, and consultants can strengthen their competitiveness and seize new business opportunities as the healthcare industry embraces the power of real-time locating systems (RTLS), condition sensing technologies, medical device connectivity, mobile communications, and enterprise-wide connectivity to provide the foundation of the “real-time enterprise.” By leveraging the platform approach, the Intelligent InSites’ partners can deliver meaningful and measurable positive outcomes resulting in lowered costs and increased revenues for healthcare providers.

The Third Annual Intelligent InSites Partner Summit will be held in October 2011 in Fargo, ND.

About Intelligent InSites

Intelligent InSites provides real-time enterprise visibility and automation solutions that transform the healthcare industry by dramatically driving down costs while improving the level of care and patient safety. By providing a single software platform capable of streamlining dozens of systems and processes using real-time location and sensory data continuously collected throughout the enterprise, Intelligent InSites helps healthcare organizations gain visibility into their operations and make profound improvements in the area of patient safety, workflow optimization, asset and inventory management, and regulatory compliance. For more information, visit www.IntelligentInSites.com.

Click here to see all recent news from this company

FLEMINGTON, NJ–(Marketwire – September 27, 2010) –  Ken Glynn, President of SpeechSwitch, Inc. (PINKSHEETS: SSWC), reported today that the first of required SEC documents to bring the company current was submitted today for EDGAR review. The third quarter, 2008 Form 10-Q has been completed and submitted to Marketwire for conversion and filing with the U.S. Securities Exchange Commission. This filing will be completed by noon tomorrow. Additional filings will be made over the next two weeks. The annual report for 2008 (end of year10-K) will be submitted by the end of this week; First quarter, 2009 Form 10Q will be filed early next week. The company has made a stepped up effort to bring the company current as a pink sheet company as quickly as possible.

Information set forth in this press release contains various “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation reform Act of 1995 (the “Act”) provides certain “safe harbor” provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management’s good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “should,” “will,” and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. 

KANKAKEE, IL–(Marketwire – September 27, 2010) –  Riverside Medical Center’s 5th annual Achieve Women’s Health Expo will take place on September 25th with the theme “Achieve health, wellness, fitness, your dreams. Achieve is a community-oriented women’s health expo through which one of the top hospitals in IL offers a variety of wellness information for women. Riverside’s women’s diagnostic center will provide free health screenings, a cooking demonstration, educational booths and healthy living presentations. 

If you live in Illinois and have the opportunity to utilize the many services of the hospitals in the Chicago area, you should definitely attend this expo. There will be several free screenings to take advantage of: EKG, glucose, pulse oximetry, blood pressure, carbon monoxide, hearing, osteoporosis, vision/glaucoma, functional balance, cholesterol and pre-diabetes. If you feel you may be at risk for any of these serious health factors, stop in and get a screening while it is on the house. Riverside Medical Center will also be offering free health risk assessments for stroke, sleep apnea, respiratory and smoking. 

In addition to these all important health screenings, a Zumba fitness exercise session will also be offered. This session will be lead by a certified Zumba instructor from the Riverside Health Fitness Center. During this high energy class you can dance your way to a healthy heart in a free-spirited, one-of-a-kind program. With easy to follow moves, you will find yourself quickly catching the beat of the Latin rhythms. A cooking demonstration will show you how to achieve heart health with delectable vegetarian entrees. An Osteoporosis lecture will focus on the novel treatment options for osteoporosis which are available at Riverside. There will also be a forum for you to learn how to balance work and life. You can learn how to create a better work-life balance with simple ideas and tips on managing and tracking time, learning to say no, nurturing yourself and more.

While this is primarily a women’s expo, men are also encouraged to attend. With mini manicures, educational booths, demonstrations, presentations, giveaways, prizes and more, you can’t afford not to attend. The Achieve Women’s Health Expo will take place on Saturday, September 25, 2010 at the Quality Inn & Suites in Bradley, IL from 8:30am to 12:30pm.

For more information about other quality services offered by Riverside Medical Center, visit www.RiversideMC.net or call (815) 933-1671.

Click here to see all recent news from this company

CENTENNIAL, CO–(Marketwire – September 27, 2010) –  Just Associates, Inc., a consulting firm specializing in patient data integrity solutions for the health information management (HIM), health informatics and health information technology (HIT) markets, today unveiled IDMaster®, an innovative software solution designed to optimize workflow when reviewing and validating potential duplicate patient records.

The announcement was made at the 82nd AHIMA Convention and Exhibit, taking place Sept. 25-30, 2010 in Orlando, Fla., where Just Associates is featuring IDMaster in Booth #1737.

IDMaster provides hospitals, health systems and other provider organizations, as well as regional health information organizations (RHIOs) and health information exchanges (HIEs), with an efficient and affordable means of reviewing and resolving duplicate patient records and preventing the occurrence of new data integrity issues. It reduces the time and resources required to reconcile potential duplicate pairs and overlap and overlay records. It also documents the validity of decisions made regarding duplicates, tracks productivity and generates comprehensive, user-friendly reports that provide a complete view of efforts and key insights into problem origination points.

“As more provider organizations migrate to electronic health record systems to take advantage of incentive funds available under the HITECH Act, many are realizing just how serious a problem duplicate patient records have become. Not only are they a significant cost drain, but the data integrity issues duplicate records cause have far-reaching implications, impacting patient safety, care and quality, and creating roadblocks to achieving meaningful use of HIT,” said Beth Just, MBA, RHIA, FAHIMA, CEO and President of Just Associates. “IDMaster delivers the features and functionality that drive more efficient duplicate reconciliation, resulting in more accurate patient records, cleaner data and a clear path toward meaningful use.”

IDMaster facilitates the review of up to eight possible duplicates in a single view and heightens user control over the merge process while lessening the time burden. It supports human review and quality assurance before records are merged and produces an export file of confirmed duplicates, non-duplicates and those records requiring additional research. The solution also supports merging records in downstream systems, reducing manual steps and associated costs.

Exempla Healthcare implemented IDMaster following an extensive MPI clean-up and transition to a new system-wide clinical information system. The Denver-based three-hospital system now relies on the software to maintain clean, high-quality patient records. 

“We recognized quickly that, without the proper tools to identify problem areas, the issue would continue to compound,” said Grant Landsbach, Exempla’s data integrity EMPI manager. “IDMaster was precisely the tool we needed. The software was easy to install, did not take up much server space and produced positive results almost immediately.”

Built with flexibility in mind, IDMaster is customizable to match the organization’s unique review processes, supporting the steps involved in identifying and validating possible duplicates and multiples. It enables the insertion of check points for quality assurance, tracks and documents each step in the workflow and features productivity tracking by individual and an audit log that records errors and corrections to drive improved performance.

IDMaster’s automated workflow technology lets provider organizations:

• Reduce the time, effort and resources associated with duplicate review and reconciliation
• Create a repeatable process tailored to individual team strengths
• Evaluate validity decisions and monitor performance at the employee or team level
• Access detailed reports based upon date, validity decision, work done by specific employees and record status

IDMaster requires little or no IT support. Its web-based deployment allows for quick implementation and features import functionality that supports most hospital information systems and/or third-party data analysis capability.

Since deploying IDMaster, Exempla has experienced a significant reduction in the resources required to manage the duplicate reconciliation process.

“You can’t play patient roulette and patient safety cannot be over-emphasized,” said Landsbach. “IDMaster has helped us improve the quality of information within our system and streamline our workflows, allowing our team to more efficiently identify and eliminate duplicates and freeing valuable resources to focus more closely on other more complex and core issues. Going forward, IDMaster will help our team continue to make strides in duplicate record management. I would definitely recommend it for most healthcare environments these days.” 

About Just Associates, Inc.
A recognized leader in health information data integrity and management, Just Associates (www.justassociates.com) is a healthcare data integration consulting firm that delivers superior value to its clients through improved data integrity. Just Associates has the process expertise and systems knowledge to deliver tailored, value-added solutions that improve financial outcomes and business processes, support delivery of quality patient care, and meet the expectations of diverse stakeholders.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – September 27, 2010) –   Ziegler (PINKSHEETS: ZGCO), a specialty investment banking firm serving hospital and healthcare systems clients since 1928, announced the promotion of John Hanley to the head of its healthcare investment banking practice. Hanley, most recently a managing director in Ziegler’s healthcare practice, will lead the healthcare team in its continued delivery of capital advisory and investment banking services to non-profit hospitals and healthcare systems throughout the country.

Tom Paprocki, CEO of Ziegler, comments about Hanley’s promotion, “John has been an integral part of our healthcare team at Ziegler for many years. He’s an excellent relationship banker and has consistently demonstrated the leadership and vision necessary to head-up our healthcare practice.”

Hanley offered, “Ziegler’s continuous commitment to the healthcare industry over the past 75+ years has resulted in many long-established relationships and new business opportunities. In addition, the expansion of our sales and trading business over the past two years has provided significantly enhanced bond distribution for our clients. I am very excited to have the opportunity to lead our team going forward.”

For more information about Ziegler, please visit us at www.Ziegler.com.

About Ziegler:
The Ziegler Companies, Inc. (PINKSHEETS: ZGCO) together with its affiliates (Ziegler) is a specialty investment bank with unique expertise in complex credit structures and advisory services. Nationally, Ziegler is ranked as one of the leading investment banking firms in its specialty sectors of healthcare, senior living, religion and education finance, as well as corporate finance and FHA/HUD. Headquartered in Chicago, IL with regional and branch offices throughout the U.S., Ziegler creates tailored financial solutions including bond financing, advisory, private placement, seed capital, M&A, risk and asset management. Ziegler serves institutional and individual investors through its wealth management and capital markets distribution channels.

Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the market value of mutual fund portfolios and separate account portfolios advised by the Company, the volume of sales by its retail brokers, the outcome of pending litigation, and the ability to attract and retain qualified employees.

ORLANDO, FL–(Marketwire – September 27, 2010) –  WellTek, Inc. (OTCBB: WTKN), a global health, fitness and wellness company, announced today that its subsidiary WellCity, the premier online destination for those into health and wellness, garnered early attention from celebrity Justin Osmond as the perfect platform to share his grandmother’s mission with the world. The Olive Osmond Perpetual Hearing Fund is the first of many charity organizations to be introduced in WellCity.

Within the next three months, WellCity will launch its online audiology ward — the WellCity Osmond Hearing Center — in its virtual Medical Center, where consumers will be able to purchase and experience industry-leading products and services for hearing loss. The Company has agreed to donate a portion of the proceeds from the WellCity Osmond Hearing Center to the Olive Osmond Perpetual Hearing Fund. In addition to this ward, the WellCity Charity web page will have a ‘Donate Now’ feature where residents of WellCity can donate directly to the Olive Osmond Perpetual Hearing Fund. The Olive Osmond Perpetual Hearing Fund’s mission is to raise deaf awareness through research and education and bring the gift of hearing to underprivileged children all across the world. “It was my grandmother’s dream that the Osmond Foundation would dedicate all of its time and resources to help the deaf,” said Justin Osmond, Founder of the Olive Osmond Perpetual Hearing Fund. Continuing, he said, “I am dedicated to fulfilling her dream and especially thrilled to partner with WellCity as we carry out this mission together.”

David George, Founder and CEO of WellCity, stated, “WellCity will be a platform to reach countless people in many significant ways. The WellCity Osmond Hearing Center is one of them. Justin is a real genuine guy whose own legacy will impact many generations to come. We are blessed to have this opportunity to work with Justin and support the Olive Osmond Perpetual Hearing Fund. WellCity can’t change the world tomorrow, but we are making a difference today.”

About the Olive Osmond Perpetual Hearing Fund
The mother of the famous singing Osmonds, known affectionately world-wide as “Mother Osmond,” made a life-long commitment to supporting new research and innovation toward improving the quality of life for the hearing impaired. The journey began with the discovery that her two oldest sons Virl and Tom were severely hearing impaired. Merrill Osmond’s 2nd son, Justin, was born with the same severe and profound hearing sensorial-neural hearing loss from which his uncles suffered. The support and love of the original four singing Osmond Brothers was manifest when they began their career in order to raise money for the best hearing devices available for their brothers. Justin was very close to his grandmother Olive and loved hearing her stories about helping deaf children. Sensing her determination to aid the hearing impaired, Justin dedicated himself to continue her passion in building her dream to greater heights, thus the establishment of the ‘Olive Osmond Perpetual Hearing Fund.’ Justin continues to carry on Olive’s legacy in helping provide the Gift of Better Hearing to children worldwide.

About WellCity Incorporated
WellCity is a social utility where health- and wellness-minded ‘residents’ can closely commune with one another; receive support, information and encouragement from their ‘neighbors’ and from a league of leading professional experts; shop for health- and wellness-oriented products and services; compete in WellCity’s proprietary 90-Day Wellness Challenge; and even enjoy income opportunities by leveraging their personal network. For more information on the Company, please visit www.WellCity.com.

About WellTek Incorporated
WellTek is a global health, fitness and wellness company that provides proven solutions to help address some of the world’s most pressing and costly health and wellness challenges. The Company owns and operates WellCity, Inc., a premier wellness-related social utility that helps ‘residents’ live happier, healthier, longer lives. The Company’s subsidiary, MedX Limited, manufactures, markets and distributes the most advanced medical exercise equipment to the medical and fitness markets. Through its wholly owned subsidiary Pure HealthyBack, Inc., WellTek is redefining healthcare delivery by providing health plans, self-insured employer groups, and consumers with a viable non-surgical, lower cost treatment for patients who are seeking lasting relief from chronic neck and back pain. For more information on the Company, please visit www.WellTekinc.com or contact [email protected].

Certain statements contained in this press release, which are not based on historical facts, are forward-looking statements as the term is defined in the Private Securities Litigation Reform Act of 1995, and are subject to substantial uncertainties and risks in part detailed in the respective Company’s Securities and Exchange Commission filings, that may cause actual results to materially differ from projections. Although the Company believes that its expectations are reasonable assumptions within the bounds of its knowledge of its businesses, expectations, representations and operations, there can be no assurance that actual results will not differ materially from their expectations. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include the Company’s ability to execute properly its business model, to raise additional capital to implement its continuing business model, the ability to attract and retain personnel — including highly qualified executives, management and operational personnel, ability to negotiate favorable future debt facilities and capital raises, and the inherent risk associated with a diversified business to achieve and maintain positive cash flow and net profitability. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will, in fact, occur.

ALISO VIEJO, CA–(Marketwire – September 27, 2010) – Enclarity, Inc., a leading healthcare information solutions company, will present a webinar on Thursday, September 30, 2010 revealing a simple way Blue Cross Blue Shield plans could improve Provider Data Quality Index (PDQI) scores by 20 percent or more. Using Enclarity’s proven ProviderPoint® solution, Blue payers can make measurable gains to improve the depth, quality and accuracy of provider data residing in their systems.

“During the past few years, we have partnered with several of the top Blue payers to great success,” said Stephanie Rose-Belcher, vice president, payer solutions, Enclarity. “We feel that we can help more Blue payers to improve their PDQI scores using our expertise in cleansing large, multi-record provider databases.”

What: Enclarity PDQI Webinar

When: Thursday, September 30, 2010

Time:  10 a.m. PDT/1 p.m. EDT

Who:  Blue plan administrators are invited to learn more about the Enclarity process and hear a case study about implementation.

Register: Register online by visiting http://www2.enclarity.com/l/414/2010-09-22/IHYVL.

About Enclarity
Enclarity^® solves healthcare’s provider information problem. The company delivers correct, current and comprehensive provider information solutions by blending thousands of data sources, advanced analytics and healthcare expertise. As a result, its clients improve results in many areas, including claims processing, provider directories, regulatory compliance and market analysis. Named one of the Top 100 private technology companies in North America by Red Herring magazine and awarded the Global Healthcare Information Technology Excellence Award by Frost & Sullivan, Enclarity is headquartered in Aliso Viejo, Calif. For more information, visit www.enclarity.com.

Click here to see all recent news from this company

SAN CLEMENTE, CA–(Marketwire – September 27, 2010) – Micro Identification Technologies, Inc. (OTCBB: MMTC), a California-based public company and creator of an advanced rapid microbial identification system, announced today that it will host a 30 minute Webinar on Wednesday, September 29, 2010 at 1:00 pm (PDT). The objective of the Webinar is to provide a general Business Update to current and prospective customers and investors. John Ricardi, MIT’s Executive Vice President, will give the presentation that will be followed by an open question and answer session with MIT’s staff including its Chairman and CEO, Michael Brennan.

Attendees may register for this Event at https://www3.gotomeeting.com/register/427693966. The session will be recorded and placed on MIT’s website for those people who are unable to attend. If you are having trouble registering or would like more information, please contact the Company at [email protected].

About Micro Identification Technologies:

MIT has developed, patented and produces a rapid microbial identification (ID) System that revolutionizes the bacteria ID process and can annually save thousands of lives and tens of millions of healthcare dollars. The MIT 1000 System identifies bacteria in minutes, not days, and at significant cost per test savings when compared to any conventional method — it is not reliant on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis — requiring only clean water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually — with food safety accounting for over $3 billion — having expanded at a rate of 9.2 percent annually since 1998. Current growth projections are at 10.2 percent annually reaching $6.2 billion by 2013 and driven by major health, safety and homeland security issues.

The MIT 1000 System can identify bacteria in less than five minutes after culturing at a cost of less than 10 cents per test and is a certified AOAC Research Institute (RI) test method of Listeria, one of three bacteria (the others are Salmonella and E.coli) that are responsible for most of the worldwide food contamination events. The Company is in the process of preparing the MIT 1000 System to become AOAC RI certified later this year for the presence of all “three” bacteria with a single mouse click. The AOAC RI Report and Certification are available from the Company. www.aoac.org 

Further, MIT has demonstrated the ability to detect and identify, within several minutes, the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus, MRSA and other pathogenic bacteria. MIT recently performed over 300 tests for the identification of these contaminants and scored 95 percent in accuracy. The System’s database currently enables the identification of over twenty species of bacteria and is easily expandable. This identification process has also been verified by North American Science Associates, Inc. (NAMSA), an independent, internationally recognized bioscience testing laboratory. The NAMSA Test Report is available from the Company and, in MIT’s opinion, documents the accuracy, speed and cost effectiveness of the MIT System over conventional processes. www.namsa.com

Please visit our website: www.micro-identification.com

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission, referencing: “MMTC”

MONMOUTH JUNCTION, NJ–(Marketwire – September 27, 2010) –  CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced the achievement of ISO 13485:2003 Full Quality Systems certification, a major milestone. ISO 13485 is an internationally recognized quality standard designed to ensure that medical device manufacturers have the necessary comprehensive management systems in place to safely design, develop, manufacture and distribute medical devices in the European Union (E.U.). It is a regulatory requirement of the E.U.’s Medical Device Directive and an important step toward attaining European CE Mark approval. 

Dr. Phillip Chan, Chief Executive Officer, stated, “We are very pleased to have attained this key milestone. ISO 13485 certification confirms that our manufacturing and quality systems meet the same high standards required of other major US medical device companies selling into Europe. Of the possible options, Full Quality Systems certification is the most stringent and efficient route to CE Mark approval for CytoSorb™ and other future CytoSorbents products. When coupled with CE Mark approval, ISO 13485 certification will allow CytoSorbents to commercialize its products in the E.U. market and other countries that recognize the ISO 13485 and CE Mark standards.”

About CytoSorbents and CytoSorb™

CytoSorbents Corporation, and its operating subsidiary CytoSorbents, Inc., is a critical care focused therapeutic device company in clinical trials to treat severe sepsis, often called “overwhelming infection,” with a novel blood purification device called CytoSorb™. Severe sepsis afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Severe sepsis is typically triggered by bacterial infections like pneumonia, or viral infections like influenza. However, it is the body’s abnormal immune response to the trigger that leads to severe inflammation and the unregulated, massive production of cytokines, often called “cytokine storm,” that then causes multi-organ failure and often death. CytoSorb™ is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped repeatedly through the CytoSorb™ cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial — a multi-center, randomized, controlled clinical trial using CytoSorb™ to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb™ in the European Union. Importantly, cytokine reduction via CytoSorb™ has broad applicability to a number of other critical care diseases where cytokine storm plays a detrimental role, including burn and smoke inhalation injury, trauma, acute respiratory distress syndrome, advanced influenza, acute pancreatitis and other. CytoSorb™ is one of a number of different resins designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy during treatment of cancer with high dose regional chemotherapy, drug detoxification and others. Additional information is available for download on the Company’s website: www.cytosorbents.com

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management’s current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company’s medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company’s products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company’s Form 10-K filed with the SEC on April 9, 2010, which is available at http://www.sec.gov.

MUNDELEIN, IL–(Marketwire – September 24, 2010) –  Kansas Governor Mark Parkinson and new CMS Deputy Administrator for the Center for Strategic Planning Tony Rodgers will be the keynote speakers at Medline Industries, Inc.’s second annual Long-Term Care Quality Summit, September 27-29 in New York City. More than 150 leaders from the nation’s long-term care community are attending the two-day forum which is focused on how nursing homes can meet the changing expectations for quality among their residents and families. 

Through panel discussions, the Summit will also address the changing regulatory expectations for the long-term care industry and how nursing homes can implement a system to continuously improve quality of care and life for their residents.

Governor Parkinson was recently named the next president of the American Health Care Association and National Center for Assisted Living (AHCA/NCAL), the nation’s largest long-term care association. Rogers is also starting in a new position with CMS, where he is responsible for enterprise-wide strategic planning, Medicare and Medicaid research and demonstrations, policy research and development and CMS enterprise decision support.

Other speakers include: Robert F. Kennedy, Jr.; Andy Kramer, MD, chief executive officer of Nursing Home Quality and professor of medicine, University of Colorado; Neil Pruitt, Jr., chairman and CEO, UHS Pruitt Corporation; Jim Foy, president and CEO, St. John’s Riverside Healthcare System, Yonkers, NY; Barbara Baylis, senior vice president of clinical operations, Kindred Healthcare, Inc.; Mary Ousley, president of Ousley & Associates; Elizabeth Ayello, president of Ayello, Harris and Associates; and Kevin Yankowsky, partner in the health law litigation group of Fulbright & Jaworski L.L.P. 

About Medline
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, IL, Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Medline has a growing network of 32 distribution centers around the country, as well as an expanding, dedicated transportation fleet with over 200 vehicles in a variety of sizes to fit customers’ specific delivery needs. The fleet is equipped with the latest navigation devices for enhanced order tracking and communication.

ALEXANDRIA, VA–(Marketwire – September 24, 2010) – The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) today announced positive clinical results demonstrating a significant efficacy advantage with Dysport™ (abobotulinumtoxinA) over Botox^® Cosmetic (onabotulinumtoxinA) for the treatment of Crow’s feet. The data were presented Friday, September 24 at a scientific session at the AAFPRS 2010 Annual Fall Meeting, taking place September 23-26 in Boston.

Downloadable photos, fact sheets and other supporting materials available here: http://www.multimedianewscenter.com/aafprs/dysport-data-shows-superiority-versus-botox-cosmetic

The 90-subject study, titled “Internally Controlled Double-Blind Comparison of Onabotulinum and Abobotulinum Toxin Type A (Nettar, Kartik D., M.D., et. al),” met its primary endpoint (p=0.01) of greater efficacy of action with Dysport™ as defined by investigator assessment of maximum contraction at Day 30 post injection compared to Day 0. Additionally, a secondary endpoint — subject assessment at maximum contraction at Day 30 compared to Day 0 — also demonstrated statistical significance with Dysport™ (p=0.027).

“Botox has long been considered the gold standard of injectables, so this data showing Dysport’s stronger efficacy is compelling,” said Corey S. Maas, M.D., F.A.C.S., AAFPRS Group Vice President for Public and Regulatory Affairs. “Since injectables are the non-surgical cosmetic procedure rising fastest in popularity, it is important to continue honing new applications for existing treatments. Dysport’s potential here is exciting as Crow’s feet are a common concern for many men and women.”

The study concluded that Dysport™ offers a quantifiable and demonstrable advantage in wrinkle effacement (shortening) and hyperfunctional frown lines compared to Botox^® Cosmetic in the treatment of Crow’s feet. Study investigators recommend further studies in additional facial regions to confirm the data.

Both Botox^® Cosmetic and Dysport™ are FDA approved for treatment of moderate-to-severe glabellar lines (vertical lines between the eyebrows); neither product is presently indicated for treatment of Crow’s feet. The study was funded by an educational grant from Medicis Aesthetics.

Additional Study Information: The randomized, double-blind, internally-controlled (split face) study was conducted at the Maas Clinic in California. Ninety subjects (75 females, 15 males) with moderate-to-severe lateral orbital rhytids (Crow’s feet) were enrolled in the study. Participants received equivalent doses of both treatments: 10 units of Botox^® Cosmetic on one side of the face and 30 units of Dysport™ on the other side. Investigator and subject gradings of Crow’s feet at relaxation and maximal contraction were obtained using the published validated dynamic and static Merz Crow’s feet grading scale before injection (Day 0) and then two, four, six, and 30 days post injection. All patients were photographed in standard five-view series at rest and at maximal contraction in a dedicated photo lane recorded by Mirror software. Additional secondary endpoints not met in the study include investigator assessment at rest at Day 30 (p=0.41) and subject assessment at rest at Day 30 (p=0.28).

About The AAFPRS: The AAFPRS is the world’s largest association of facial plastic and reconstructive surgeons with more than 2,700 members — whose cosmetic reconstructive surgery focuses on the face, head and neck. Academy fellows and members are board-certified and subscribe to a code of ethics. In addition, the AAFPRS provides consumers with free information and brochures and a list of qualified facial plastic surgeons in their area by visiting the AAFPRS website, www.facemd.org.

SIOUX FALLS, SD–(Marketwire – September 24, 2010) –  The American Diabetes Association, the nation’s leading voluntary health organization in the fight against diabetes, announces several leading Special Diabetes Program for Indians (SDPI) grantees presented with the John Pipe Voices For Change Award in recognition of their effective diabetes treatment and prevention services in American Indian and Alaskan Native communities. The awards were presented at the National Indian Health Board’s 27^th Annual Consumer Conference on Wednesday, September 22^nd in Sioux Falls, South Dakota. 

“At nearly 17%, Alaska Natives have the highest age-adjusted prevalence of diabetes among all U.S. racial and ethnic groups,” said Gale Marshall, Chair of the American Diabetes Association’s Awakening the Spirit Native American initiative. “The John Pipe Voices For Change awards give us the opportunity to honor selected programs for their outstanding achievements in the delivery of diabetes prevention and treatment services in tribal communities. By showcasing these programs we are also acknowledging over 450 SDPI programs and their valuable efforts to stop diabetes.”

The name of these awards was changed to honor long-time diabetes supporter John Pipe of Wolf Point, Montana, who passed away earlier this year. Pipe was a dedicated diabetes advocate and served as a member of the Awakening the Spirit Subcommittee. His longstanding advocacy efforts reached from his local community to Washington, DC and impacted countless tribal communities. 

The 2010 John Pipe Voices For Change Award recognizes SDPI programs that have excelled in the following categories: Advocacy, Outcomes, and Innovation.

Advocacy Award:
Hualapai Healthy Heart Program
Peach Springs, Arizona
The Hualapai Healthy Heart Program is an SDPI funded demonstration project designed to reduce cardiovascular disease, the most compelling complication of diabetes among their participants. They have engaged their greater community in a variety of successful advocacy efforts having a local, regional and national impact.

Outcomes Award:
Bristol Bay Area Health Corporation (BBAHC)
Dillingham, Arkansas
BBAHC Diabetes Prevention/Lifestyle Change Program provides a comprehensive array of programs in effort to prevent diabetes or diabetes related complications spanning 34 villages within the Bristol Bay region. Programs work on improving individuals’ rates of diabetes, nutrition and exercise education, as well as lowering blood pressure.

Innovation Award:
Tuba City Diabetes Treatment and Prevention
Tuba City, Arizona
The Department of Diabetes Treatment and Prevention Services at the Tuba City Regional Health Care Corporation (TCRHCC) has employed innovative approaches that have resulted in community wide collaborations to effectively provide diabetes prevention and treatment services.

Honorable Mentions:

Advocacy Honorable Mention:

• Native American Rehabilitation Association of the Northwest (NARA) Diabetes Treatment & Prevention Program (Portland, Oregon)
• Cow Creek Health & Wellness Center (Roseburg, Oregon)

Outcomes Honorable Mentions:

• SDPI Diabetes Prevention Program Warm Springs Health and Wellness Center Indian Health Services (Warm Springs, Oregon)
• American Indian Health and Family Services (AIHFS) Diabetes Program (Detroit, Michigan) 

Innovation Honorable Mention:

• Chickasaw Nation Division of Health (Ada, Oklahoma)

The SDPI continues to give Indian health programs and tribal communities the resources and tools they need to both prevent and treat diabetes. It funds more than 450 community directed programs, offering local tribes and health programs the opportunity to set priorities that meet the needs of the community, whether it be prevention activities or treatment. For over a decade Congress has provided funding for the SDPI and the American Diabetes Association has played an integral part in promoting this important program. The Association will continue to work for strong support of SDPI.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

LOS ANGELES, CA–(Marketwire – September 24, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (MMR) announced today that it has successfully opposed a Summary Judgment Motion brought by the Lymphoma Research Foundation (LRF) as part of its efforts to protect a portion of the Company’s intellectual property, which it previously disclosed on May 3, 2010.

The Company acquired the biotech assets from its reverse merger with Favrille, Inc., a San Diego biotech company, in January 2009. Over the past year, MMR identified a collection of these biotech assets, which include biotech samples that were in the possession of the Lymphoma Research Foundation. They do not include other pre-merger biotech assets, including the Company’s anti-CD20 monoclonal antibodies, results of clinical trials data, patents and other intellectual property.

According to declarations filed on behalf of MMR, the Company understands that the biotech samples could have a value as high as $1.376 million. However, based on other information currently maintained by the Company, the samples could have a far greater value, depending on the extent and depth of the clinical data collected at trial initiation, the extent and depth of the clinical data collected during patient follow-up, whether follow-up tissue samples are available, and whether accompanying whole blood or serum is available from patients from trial enrollment or during trial progression.

Robert H. Lorsch, Chairman and CEO of MMRGlobal, said, “We are pleased by this early ruling. When combined with clinical data from the Company’s vaccine research into the causes and potential treatment of B-Cell Non-Hodgkin’s Lymphoma, including data from patient follow-ups which the Company has, the value could be significant.”

The Company understands its intellectual properties may also be of value in a possible reinterpretation of the pre-merger Favrille vaccine trials and that the IP may also unlock ways to create other “custom-made” cancer vaccines and be valuable in discovering additional opportunities in cancer research. The Company hopes to enter into licensing agreements with biopharmaceutical companies, academic institutions, research organizations and others regarding the use of its assets.

About MMRGlobal, Inc.
MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements
Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, statements regarding MMRGlobal, Inc.’s assets including but not limited to its primary Health IT businesses, samples and data from vaccine and clinical trials, and anti-CD20 antibody assets. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the development and approval of biotechnology/biopharmaceutical product candidates and Health IT products and additional risks discussed in the Company’s filings with the Securities and Exchange Commission. All subsequent written and oral forward-looking statements attributable to the Company (or any person acting on the Company’s behalf) are qualified by the cautionary statements in this notice. MMRGlobal, Inc. is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information.

Click here to see all recent news from this company

SUNNYVALE, CA–(Marketwire – September 24, 2010) – Spiracur, Inc. today announced important results from a clinical study highlighting the safety and efficacy of its SNaP Wound Care System for the treatment of chronic lower extremity wounds. The data was presented this week at the Fall 2010 Symposium on Advanced Wound Care (SAWC) in Anaheim, Calif.

The 12-center, 65-patient randomized controlled trial (RCT) compared negative pressure wound therapy (NPWT) between the KCI Wound V.A.C. Therapy System and the SNaP Wound Care System for the treatment of chronic lower extremity wounds. The Poster was presented by David G. Armstrong, DPM, M.D., Ph.D., William A. Marston, M.D., Alexander M. Reyzelman, DPM and Robert S. Kirsner, M.D., Ph.D. The subjects were randomly assigned to treatment with either the SNaP System or the V.A.C. System, and the trial evaluated treatment for up to 16 weeks, or until there was complete closure of the ulcer.

Planned interim analysis of the first 65 patients from 12 centers found no significant differences in the proportion of subjects healed between the two devices evaluated or in percent wound size reduction. Non-inferiority was demonstrated between the two therapies in percent wound size reduction to the *p < 0.05 significance level. The study also found no significant differences in wound related complications such as wound infections.

According to David G. Armstrong, DPM, M.D., Ph.D., professor of surgery at the University of Arizona and principal investigator on this study, “We have been using the technology for over a year now and our patients have responded well to this new portable therapy. For those of us dedicated to healing wounds and preventing amputations, this device provides an important tool for treating these chronic conditions. This novel technology may prove to hold substantial potential for patients requiring smaller NPWT treatment options.”

“We are thrilled to have such positive clinical data presented at SAWC, as they clearly demonstrate the unique opportunity the SNaP Wound Care System offers to patients and clinicians for the treatment of chronic wounds,” said Gary Restani, president and chief executive officer, Spiracur, Inc. “The response to our proprietary system has been extremely positive by both patients and clinicians, and we are confident that this new data will help increase awareness for and broaden adoption of the SNaP Wound Care System.”

About the SNaP Wound Care System:
The SNaP Wound Care System is an ultraportable negative pressure wound therapy (NPWT) device that was approved by the U.S. Food & Drug Administration (FDA) in August 2009 in a new therapy category the FDA has defined as “non-powered” NPWT devices. The SNaP System provides the same level of negative pressure as competitive technologies; however, it requires no electric or battery power. In addition, the SNaP System, unlike powered NPWT, is silent, small and lightweight (weighing less than 3 oz.), which enables patients to wear the device under clothing and resume daily activity without exposing their wound care treatment to the world.

The FDA determined that the SNaP System is indicated for patients who would benefit from a suction device particularly as the device may promote wound healing. The SNaP System is used for the removal of small amounts of exudate from chronic, traumatic, dehisced, acute, subacute and ulcer (diabetic or pressure) wounds. Additional information can be found by visiting http://www.spiracur.com/snapproduct.html.

About Spiracur, Inc.
Spiracur, Inc. is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford Biodesign Innovation Program in 2007. Its first product, The SNaP Wound Care System, grew out of the notion that current negative pressure wound therapies were too cumbersome for patients and clinicians. Spiracur strives to develop products that are truly patient-centric. For more information, please visit http://www.spiracur.com.
SNaP, Spiracur and the Spiracur Design are registered trademarks of Spiracur Inc.

id=”nav_links”>

BIRMINGHAM, UNITED KINGDOM–(Marketwire – Sept. 24, 2010) – Shocking research has revealed that the UK is a nation of overweight people, with many classed as dangerously overweight or morbidly obese.

Figures from the Office for National Statistics show that 24.5 per cent of adults in England were classed as obese in 2008, amounting to an 8.8 per cent increase since 1994 when only 15.7 per cent of adults were classed as dangerously overweight.

As concerns for the state of people’s health in the UK grow, so too does the amount of people who are dangerously overweight sparking fears that the UK is stuck in the middle of an obesity crisis that shows no signs of slowing down.

According to the World Health Organisation, also known as WHO, the UK has featured far more frequently in the their top 10 most obese nations list in the last few years and according to Nation Master.com the UK is ranked as the third most overweight nation only to be beaten by Mexico and the United States.

With 46 per cent of men in England and 32 per cent of women in England classes as overweight and an additional 17 per cent of men and 21 per cent of women classed as obsess it is hardly surprising that the NHS has seen an increase in the number of surgical procedures performed on obese patients in the last five years.

Those who are worried about being overweight should book a consultation with an expert bariatric surgeon at The Hospital Group.

The Hospital Group is the UK’s biggest provider of weight loss surgery, including gastric bands, gastric bypasses and gastric balloons.

David Ross, Chief Executive of The Hospital Group said: “Being overweight can affect every aspect of your life. Not only does it have a huge impact on your health, putting you at risk of diabetes, heart disease, strokes and depression but it can also cause low self esteem and confidence.

“Those who are overweight often find themselves in a vicious circle, they want to lose weight and become more healthy but are locked in a battle with overeating and don’t know how to change their bad and harmful eating habits.

“Our consultants ensure that, as well as having an absolute need for a gastric procedure, the patient understands that weight loss surgery isn’t a miracle cure and they would need to work with the band to achieve the healthier lifestyle they desire.”

Since The Hospital Group was established in 1992, it has risen to become the UK’s biggest weight loss surgery providers, performing more gastric procedures last year than the NHS.

The Hospital Group is committed to providing the very highest standards and all procedures are performed by an expert medical team in state-of-the-art facilities that are second to none.

For further information of The Hospital Group’s range of weight-loss procedures, surgery-seekers should visit the website www.thehospitalgroup.org or call our patient care coordinators on 0845 762 6727.

NEW YORK, NY and HALIBURTON, ON–(Marketwire – September 23, 2010) – October is National Dental Hygiene Month (NDHM) and it’s also the perfect time to create new dental marketing materials to reach out to your dental patients, says Patient News, a leading dental marketing solutions company.

Effective dentist/patient communication is essential to keeping patients, and a multi-channel patient retention campaign is extremely effective because it’s a means of sharing ideas and knowledge, not selling. NDHM is a great time for dental practitioners to ramp up their communication/marketing efforts and provide much needed and appreciated dental patient education to their patients.

“To build a vibrant and profitable practice it’s important to include a patient-centered marketing approach. Even the healthiest practice can’t help but lose patients over time due to natural attrition, competition, dissatisfaction, and perceived indifference,” said Karen Galley, President of Patient News. “Perceived indifference sends customers away nearly five times more often than dissatisfaction and seven times more often than for competitive reasons. A patient newsletter shows your patients you care.”

A consistent effort to communicate and educate patients, especially when paired with the efforts of the American Dental Hygienists’ Association in October, can reap measurable rewards. The ADHA website includes information to help promote events planned in honor of NDHM. Patient News can improve dentist/patient communications through their extensive resources, including an exceptional article library featuring stories about the importance of dental hygiene — clearly linked to overall health and systemic diseases.

“Although people continue to score smile and appearance of teeth as most important to their personal appearance and place a high value on oral health, more than 80% remain fearful of the dentist. It takes time and quality dental patient education via email and mail to encourage existing and prospective patients to make even a positive change,” said Galley. This type of communication can also assist dentists reduce no shows and cancellations, improving the overall health of the practice and patient community.

For more information on NDHM, visit ADHA.org. For additional information on dental newsletters or dental email newsletter options from Patient News call 800.667.0268 or visit www.Patientnews.com.

Read more: http://www.patientnews.com/pressreleases/educate-patients-during-dental-hygiene-month.html.

About Patient News:

Patient News is North America’s most trusted resource in helping dental practices succeed. The company produces award-winning healthcare and dental marketing products in Canada, the United States, and the United Kingdom.

Click here to see all recent news from this company

TORONTO, ONTARIO–(Marketwire – Sept. 22, 2010) –

Attention: Health and Science Reporters, Assignment and Photo Editors. 

On September 23 2010, media are invited to an in-depth briefing with senior scientists on current stem cell research activity at the McEwen Centre for Regenerative Medicine. McEwen Centre Director, Dr. Gordon Keller will discuss eight “Accelerated Discoveries.” These are research initiatives that include a new project that will push the frontier forward for patients suffering from heart disease, the number one killer in the western world. 

Research at the McEwen Centre also holds important implications for diabetes, lung disease, diseases of the blood as well as neurodegenerative disease.

Please join us to learn more about this exciting research field. The tour will include an opportunity to interview senior scientists and gain new understanding of the latest developments in this cutting edge research. You are also invited to attend a Public Symposium on The Stem Cell Healthcare Revolution which follows the tour at 1:30 p.m. to 3:30 p.m.

Telephone interviews with senior scientists, the McEwens, and patient advocates can be arranged in advance.

LAS VEGAS, NV–(Marketwire – September 22, 2010) –  Medex, Inc. (PINKSHEETS: MDXX), today announced four strategic hires and several facilities expansions intended to foster significant revenue and earnings growth at the Company’s Creative Rehab Technology Services, Inc. and Bee Mobile, Inc. operations.

Kia Davis, 35, has been appointed service coordinator for Creative Rehab and will be based in that company’s newly relocated and expanded facility in Rancho Cucamonga, California. Davis will be responsible for new business development in the greater Los Angeles area as well as contracts management with a growing dealer network there and throughout the Inland Empire.

Additionally, Michael Spradley, 40, has been hired as a seating and mobility specialist. With significant industry contacts and related sales experience, he will be supported by two additional technician hires in San Diego and Escondido, California. These individuals will support sales at Creative Rehab and servicing contracts for Bee Mobile.

In related matters, Medex indicated that facility expansions are in progress at Creative Rehab’s headquarters in Chula Vista, California and that Bee Mobile, in addition to the above referenced Rancho Cucamonga relocation, has acquired an additional 5,000 square foot repair and warehouse facility in Fontana, California to improve efficiency and output of its capacities.

Medex also indicated that Bee Mobile is currently finalizing contractual arrangements with several dealers in the greater Las Vegas area to provide services and repair.

“Growth in demand for products and service necessitate capital investment for both plant infrastructure as well as key personnel. We anticipate that this investment should yield a 30% revenue growth for both companies combined with previously disclosed corresponding cumulative net margin improvement,” said Paul Protzman, President of Medex, Inc. “We are encouraged by current market response to these business lines.”

About Medex, Inc.

Medex, Inc. is a development stage Nevada-based medical support services company, which plans to grow through acquisitions of medical supply companies, medical technology companies, and assisted living and care facilities worldwide. For additional information, see www.medexsynergies.com.

Safe Harbor Statement:

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan,” or “planned,” “will,” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

OAKBROOK TERRACE, IL–(Marketwire – September 22, 2010) –  Accredited hospitals in the United States are providing higher-quality, evidence-based care for heart attack, pneumonia, surgical care and children’s asthma care, according to Improving America’s Hospitals: The Joint Commission’s Report on Quality and Safety 2010. The report presents scientific evidence of improvement and how it relates to these common medical conditions and procedures.

“It is very encouraging that this year’s report shows high rates of performance on these critical process measures and high levels of consistent excellence among hospitals on many measures,” said Mark R. Chassin, M.D., M.P.P., M.P.H., president, The Joint Commission. “Hospitals devote enormous resources and energy to using these performance measures to drive improvement in their clinical processes. This report demonstrates that these efforts are resulting in consistently improving patient care in America’s hospitals.”

The fifth annual report shows continual improvement over an eight-year period on accountability measures — quality measures that meet four criteria designed to identify measures that produce the greatest positive impact on patient outcomes. For example, the 2009 heart attack care result is 97.7 percent, up from 88.6 percent in 2002. A 97.7 percent score means that hospitals provided an evidence-based heart attack treatment such as aspirin at arrival and beta-blockers at discharge 977 times for every 1,000 opportunities to do so.

The data, drawn from more than 3,000 accredited hospitals, show:

• Significant progress in consistently using evidence-based treatments. In 2002, hospitals achieved 81.8 percent composite performance on 957,000 opportunities to perform care processes related to accountability measures. In 2009, hospitals achieved 95.4 percent composite performance on 12.5 million opportunities — an improvement of 13.6 percentage points.
• Hospital performance on measures of quality relating to inpatient care for childhood asthma has increased dramatically in the two years since being introduced. The 2009 children’s asthma care result is 88.1 percent, up from 70.7 in 2007.
• The 2009 pneumonia care result is 92.9 percent, up from 72.4 percent in 2002 — an improvement of 20.5 percentage points.
• The surgical care result improved to 95.8 percent in 2009 from 77.4 percent in 2004.

Although hospitals achieved 90 percent or better performance on most individual process of care measures, the report contends that more improvement is needed. For example, hospitals finished 2009 with relatively low performance on the following two measures introduced in 2005:

• Providing fibrinolytic therapy within 30 minutes of arrival to heart attack patients — only 55.2 percent of hospitals achieved 90 percent compliance or better.
• Providing antibiotics to intensive care unit pneumonia patients within 24 hours of arrival — only 67.5 percent of hospitals achieved 90 percent compliance or better.

The report, which focuses on accountability measures for the first time, is an effort to clearly demonstrate the impact that performance measures have on improving patient outcomes. Doing so will strengthen the partnerships hospitals have with physicians, nurses, pharmacists and other clinicians who are engaged in the hard work of improving the processes of care. Specific expectations for performance on accountability measures will be included in hospital accreditation standards by 2012.

Quality, safety and patient satisfaction results for specific hospitals can be found at www.qualitycheck.org. For a complete copy of the report Improving America’s Hospitals: The Joint Commission’s Report on Quality and Safety 2010, please visit www.jointcommission.org.

Founded in 1951, The Joint Commission seeks to continuously improve health care for the public, in collaboration with other stakeholders, by evaluating health care organizations and inspiring them to excel in providing safe and effective care of the highest quality and value. The Joint Commission evaluates and accredits more than 18,000 health care organizations and programs in the United States, including more than 9,700 hospitals and home care organizations, and more than 6,800 other health care organizations that provide long term care, behavioral health care, laboratory and ambulatory care services. In addition, The Joint Commission also provides certification of more than 1,700 disease-specific care programs, primary stroke centers, and health care staffing services. An independent, not-for-profit organization, The Joint Commission is the nation’s oldest and largest standards-setting and accrediting body in health care. Learn more about The Joint Commission at www.jointcommission.org.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – September 22, 2010) – ForceLogix Technologies Inc. (TSX-V: FLT) www.ForceLogix.com (the “Company“) announced today that effective September 22, 2010, 340,216 common shares were issued to an Insider (as that term is defined in Exchange Policy 1.1) upon conversion of certain special warrants originally issued to holders at the closing of the Company’s Qualifying Transaction on November 30, 2009. Following issuance of said common shares, the Company has 61,202,615 common shares and 22,552,060 non-exercised special warrants outstanding. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Click here to see all recent news from this company

CLIFTON, NJ–(Marketwire – September 22, 2010) –  Electronic Control Security, Inc. (OTCBB: EKCS) (ECSI), a leading provider of a broad line of electronic security system technologies to the government and private sectors, announced financial results for the fiscal year ended June 30, 2010.

Arthur Barchenko, President and CEO, stated, “We achieved our objective during fiscal 2010 to change the direction of the Company’s marketing effort from that of a prime contractor to the Department of Defense to that of a technology manufacturing resource and support service provider to the large system integrators, dealers/installers and, in certain cases, the end user i.e. nuclear power stations.

“To that end, we achieved net revenues of $4,513,737 for fiscal year 2010 as compared to $3,472,696 for fiscal year 2009, representing an increase of approximately 30%. The increase in net revenues during 2010 as compared to 2009 is attributable equally to increases in both government and private-sector related purchase orders.”

Gross margins for 2010 were 55% as compared to 28% of revenue for the 2009 Period. The increase in gross margin for the fiscal year ended June 30, 2010 compared to the corresponding period in 2009 is primarily attributable to a change in the order mix of equipment sales and support services. We experienced an increase in both higher margin equipment sales as well as design and engineering support service billings which, combined, resulted in the increase in gross margins for the Fiscal 2010 Period.

Selling, general and administrative expenses increased approximately 34% in the 2010 Period to $1,771,923 from $1,318,910 in 2009. The increase is partially attributable to costs relating to the U.N. project in Ethiopia where we incurred significant increases in freight and marketing related expenses. However, the major increase in costs related to management’s decision to recognize and write off certain receivables totaling $629,437 related to two overseas projects in Asia and the Middle East and uncollectible Department of Defense (DoD) program-related expenses. Although we attempted to resolve these issues during the past year, we have not been able to collect these receivables. Based on these results, management has made the decision not to seek the award of DoD prime contracts in the future. 

Mr. Barchenko stated that, “I am also pleased to announce that, on July 30, 2010, the Company paid off the principal balance of $100,000 plus interest completing its short and long-term convertible principal debt obligations.

“During fiscal 2010, the Company submitted proposals on projects for Department of Defense facilities and certain nuclear power stations in the United States and southeast Asia valued at approximately $13,650,000. A number of these DoD and nuclear projects amounting to $2.2 million was awarded and partially shipped during the fourth quarter of fiscal 2010. Most of these proposals are still pending and awaiting approval, funding and award. We anticipate decisions relating to these remaining proposals within the first half of fiscal 2011 with deliveries scheduled through the last six months of fiscal 2011 with deliveries scheduled through the last six months of fiscal 2011 and the first half of fiscal 2012.”

About ECSI

ECSI is a global leader in perimeter security and a quality provider to the Department of Defense, Department of Energy, nuclear power stations, and other large commercial-industrial complexes. The Company designs, manufactures and markets physical electronic security systems for high profile, high threat environments utilizing risk assessment and analysis to determine and address the security needs of its customers. Teaming agreements with major system integrators enable ECSI to support the installation and aftermarket of its products in the U.S. and overseas. ECSI is located at 790 Bloomfield Avenue, Bldg. C-1, Clifton, NJ 07012. Tel: 973-574-8555; Fax: 973-574-8562. For more information on ECSI and its customers, please visit http://www.ecsiinternational.com.

ECSI INTERNATIONAL, INC. SAFE HARBOR STATEMENT: This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to changes in economic conditions generally and in our industry specifically, changes in security technology, legislative or regulatory changes that affect us, the availability of working capital, timing of purchase orders, acceptance of company proposals, changes in costs and the availability of goods and services, the introduction of competing products, changes in our operating strategy or development plans, our ability to attract and retain qualified personnel, changes in our acquisition and capital expenditure plans, sufficiency of cash reserves and the risks and uncertainties discussed under the heading “RISK FACTORS” in Item 1 of our Annual Report on Form 10-K for the fiscal year ended June 30, 2010 and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

NORTHFIELD, IL–(Marketwire – September 22, 2010) – Pharos Innovations today congratulated the Care Continuum Alliance on the launch of its new brand and ongoing work on behalf of organizations and individuals providing healthcare at all stages of well-being.

The Care Continuum Alliance, established in 1999 as the Disease Management Association of America, has completed its transition to a new name and brand that reflect the industry’s evolution toward care across the continuum of health, from wellness and prevention to care management and more complex interventions.

Pharos Innovations, a Care Continuum Alliance member represented on the association’s Board of Directors, provides a unique IVR and Web-based remote patient monitoring/behavior change technology through its Tel-Assurance^® program.

“The continuum of care is as much about keeping the healthy well and minimizing health risks as it is about managing specific conditions,” said Randall E. Williams, MD, CEO of Pharos Innovations. “With its new brand, the Care Continuum Alliance captures the broad variety and value of programs and products we and other CCA members provide.”

Care Continuum Alliance (CCA) members are uniquely positioned to contribute to new models of care and the drive toward wellness, prevention and health information technology spurred by federal reform initiatives. Pharos Innovations and other CCA members offer extensive expertise in health risk assessment, innovative technologies to promote healthful behaviors, care coordination across multiple settings and physician collaborations — skills and activities at the core of the reform law.

Pharos Innovations will exhibit this year at The Forum 10, the annual meeting of the Care Continuum Alliance, Oct. 13 to 15, in Washington, D.C. Visit Pharos at booth #416, at the Hilton Washington hotel, the Forum host site. Learn more about the Forum at TheForum10.org.

About Pharos Innovations
Pharos Innovations is actively involved in transforming the U.S. healthcare delivery system. Pharos offers IVR and Web-based behavior change services and tools that enable payers and providers to cost-effectively and efficiently manage their chronic care population.

Pharos’ main offering, Tel-Assurance, engages, motivates and drives improved self-care. Through Tel-Assurance, participants self-report their health status daily through the phone or Web. This unique approach actively engages individuals with chronic conditions in their healthcare and provides care managers/nurses with real-time information to intervene before symptoms escalate. Tel-Assurance has been proven an effective way to reduce avoidable, all-cause hospital admissions and readmissions and reduce overall healthcare costs among diverse populations.

The Pharos’ solution is strongly validated to show measured clinical improvement and financial impact, is the recipient of the prestigious American Heart Association National Outcomes award and was selected for the first ever National Institutes of Health (NIH) sponsored evaluation of remote monitoring interventions. For more information visit www.pharosinnovations.com or join in on the discussion at our blog, www.thecollaborativeforum.com.

id=”nav_links”>

NEW YORK, NY–(Marketwire – September 22, 2010) –  Send Word Now, the leading provider of emergency notification and on-demand incident management, alerting, and response services, announced today that The Wisconsin Hospital Emergency Preparedness Program will make Send Word Now’s Alert Service available to all hospitals in Wisconsin. The initiative sets a new standard for hospital management and a model for unified communications across a state-wide health care network.

“We were looking for a notification system that could meet our communications needs, and specifically for a system that is easy to use,” affirmed Bob Ritger, Operations Officer for the Emergency Preparedness Program. He added, “Having one system throughout the state will allow us to implement our messaging strategies more easily and consistently throughout Wisconsin hospitals. We look forward to working with Send Word Now on this project over the long-term.”

Tony Schmitz, President and CEO of Send Word Now, said, “We are extremely proud to be able to provide our services to hospitals in Wisconsin. Send Word Now is well suited to support these hospital emergency preparedness initiatives based on its experience and expertise in servicing healthcare providers and hospitals across the country.” 

About Send Word Now

Send Word Now is the leading provider of on-demand alerting and incident management services for both routine and emergency communication. The easy-to-use, web-based emergency notification service is used by government agencies, municipalities, universities, non-profit organizations and businesses, including many Fortune 500 companies, to ensure fast, effective, two-way communication in real-time. Send Word Now’s Alert Tracer® provides a full audit trail of messages sent and received for after-action reporting and follow-up. Designed to reach anyone, anywhere, anytime, with any device over any type of connection, Send Word Now’s mass notification system is capable of transmitting hundreds of thousands of voice and text messages in minutes. The company is headquartered in New York City. Visit Send Word Now on the web at http://www.sendwordnow.com or email us at [email protected]. Follow Send Word Now on Twitter at http://twitter.com/sendwordnow and check out our new blog for industry news and insights at http://www.sendwordnow.com/Company/Blog.

About The Wisconsin Hospital Emergency Preparedness Program

The Wisconsin Hospital Emergency Preparedness Program supports hospital emergency preparedness planning and response to mass casualty incidents or pandemic events. The Wisconsin Hospital Emergency Preparedness Program is funded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (DHHS). 

Click here to see all recent news from this company